Lecanemab的开发商卫材在今日发表声明[4]，公布了Lecanemab在美国的定价措施。基于每双周一次10mg/kg的剂量，按照Study 201和Clarity AD中受试者的平均体重75kg，患者的年度医疗成本约为26500美元。考虑不同药品包装容量，这一数字可能略有波动。

他们还指出，在完成A 显著清除后，或可采取低剂量的维持给药方案，这能进一步降低医疗费用。

参考资料：

[1]https://www.fda.gov/news-events/press-announcements/fda-converts-novel-alzheimers-disease-treatment-traditional-approval

[2]https://www.alzforum.org/news/conference-coverage/lecanemab-sweeps-toxic-av-protofibrils-catches-eyes-trialists

[3]https://molecularneurodegeneration.biomedcentral.com/articles/10.1186/s13024-023-00637-0

[4]https://www.prnewswire.com/news-releases/eisais-approach-to-us-pricing-for-leqembi-lecanemab-a-treatment-for-early-alzheimers-disease-sets-forth-our-concept-of-societal-value-of-medicine-in-relation-to-price-of-medicine-301715694.html